We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Leprosy remains a challenge, both for sufferers and the health workers who treat them. There may be persistent nerve damage, and the disease carries a social stigma. Treatment must therefore be broad-based to be successful.

In this article, Diana N. J. Lockwood, consultant leprologist at London's Hospital for Tropical Diseases, and Bhushan Kumar, professor of dermatology at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, say that the multiple drug regime recommended by the World Health Organisation is still the best treatment. There is, they say, little evidence that other drug combinations and shorter regimes are working.

And for truly effective treatment, there needs to be more than drugs alone. An integrated response that combines counselling, testing for nerve damage, steroid treatment and a bigger input from dermatologists is the best way forward.

Link to full article in the British Medical Journal

Reference: British Medical Journal 328, 1447 (2004)

Related topics